IRD Opus Genetics, Inc.
Price Chart
Executive Summary
Opus Genetics reported positive clinical data for its LCA5 gene therapy (OPGx-LCA5) showing over 30-fold improvement in cone sensitivity and visual acuity gains in pediatric patients. Early BEST1 data also showed improved visual acuity and retinal structure in adults. The results support broad pipeline potential and regulatory readiness.
Actionable Insight
Positive clinical data may drive near-term interest in IRD shares. Key catalyst is BEST1 Cohort 1 data in September 2026. Monitor for further enrollment and safety updates.
Key Facts
- OPGx-LCA5: >30-fold improvement in cone sensitivity, visual acuity gains, well-tolerated in pediatric LCA5 patients at 6 months.
- OPGx-BEST1: up to 12-letter visual acuity improvement, ~23% reduction in central subfield thickness in first adult participant at 3 months.
- Preclinical RHO data show durable retinal preservation and support mutation-independent approach.
- BEST1 Cohort 1 topline data expected September 2026.
Financial Impact
No revenue or earnings impact; early-stage clinical data. Positive readthrough for pipeline value but pre-commercial.
Risk Factors
- Early-stage data; larger trials needed to confirm efficacy and safety.
- Regulatory and manufacturing risks for gene therapies.
- Potential dilution from future capital raises.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290656 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
9d ago
|
S-3
| $4.61 awaiting T+5 | awaiting T+5 | — | $4.04 (+12.36%) |
|
May 12, 2026
4w ago
|
8-K
| $5.18 $4.44 | ▼ −14.29% | ▼ −14.36% | $4.04 (−22.01%) |
|
May 12, 2026
4w ago
|
Press Release
| $5.18 $4.44 | ▲ +14.29% | ▲ +14.36% | $4.04 (+22.01%) |
|
May 7, 2026
5w ago
|
Press Release
| $4.99 $4.97 | ▼ −0.40% | ▼ −1.86% | $4.04 (−19.04%) |
|
Apr 24, 2026
7w ago
|
8-K
| $5.12 $5.22 | ▲ +1.95% | ▲ +1.55% | $4.04 (−21.09%) |
|
Apr 23, 2026
7w ago
|
EFFECT
| $5.21 $4.67 | ▼ −10.36% | ▼ −11.84% | $4.04 (−22.46%) |
|
Apr 23, 2026
7w ago
|
Insider Cluster
| $5.21 $4.67 | ▼ −10.36% | ▼ −11.84% | $4.04 (−22.46%) |
|
Apr 10, 2026
9w ago
|
Press Release
| $5.36 $5.75 | ▲ +7.28% | ▲ +2.77% | $4.04 (−24.63%) |
|
Apr 7, 2026
9w ago
|
8-K
| $4.92 $5.55 | ▲ +12.80% | ▲ +7.48% | $4.04 (−17.89%) |
|
Mar 16, 2026
13w ago
|
Insider Cluster
| $5.19 $4.59 | ▼ −11.56% | ▼ −9.52% | $4.04 (−22.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access